NYRADA INC. — Investor Presentation 2021

Mar 17, 2021

1

==> picture [112 x 113] intentionally omitted <==

==> picture [89 x 89] intentionally omitted <==

==> picture [89 x 89] intentionally omitted <==

2

==> picture [89 x 89] intentionally omitted <==

Vision

==> picture [22 x 23] intentionally omitted <==

==> picture [22 x 23] intentionally omitted <==

Reduce risk of cardiovascular disease (heart attack and stroke) Deliver the first-ever treatment to prevent brain damage following stroke and head trauma (falls, motor vehicle accidents) Improve survivability, reduce disability

Mission

3

==> picture [89 x 89] intentionally omitted <==

Cholesterol-Lowering drug Oral PCSK9 inhibitor to be used alone as a monotherapy, or in combination with a statin - Out-license following Phase I study

Brain Injury drug Intravenous and intranasal drug to help people who sustain a traumatic brain injury (TBI) or suffer a stroke (NYX-1010 compound) - Out-license following Phase II study

Innovative Treatments Best-in-Class / First-Line

Clinical Need Market Potential Strong Patent Protection Commercialise Early

4

==> picture [89 x 89] intentionally omitted <==

High LDL Cholesterol leading cause of cardiovascular disease Cardiovascular disease responsible for 1-in-4 deaths[1]

62.6 million US adults with elevated LDL-C[2]

==> picture [346 x 195] intentionally omitted <==

5

==> picture [89 x 89] intentionally omitted <==

==> picture [201 x 201] intentionally omitted <==

==> picture [45 x 44] intentionally omitted <==

19.4 million

Unable to achieve LDL-C target despite taking statin therapy

==> picture [43 x 43] intentionally omitted <==

6

Current PCSK9 Inhibitors

==> picture [89 x 89] intentionally omitted <==

==> picture [331 x 161] intentionally omitted <==

Binds to PCSK9 protein Blocks action of PCSK9 on cholesterol receptor

Effective , combined with a statin Expensive US$5,800 per year Inconvenient (2-4 weekly injections) Statin + current PCSK9 inhibitor = expensive and inconvenient

7

==> picture [89 x 89] intentionally omitted <==

Oral PCSK9 Convenient treatment for patient

Costeffective

Small molecule PCSK9 inhibitor overcomes longstanding challenge of oral treatment

Can be combined with statin to deliver a first ever single pill PCSK9/statin treatment

==> picture [330 x 303] intentionally omitted <==

8

==> picture [89 x 89] intentionally omitted <==

==> picture [554 x 233] intentionally omitted <==

==> picture [499 x 148] intentionally omitted <==

9

Brain Injury Problem

==> picture [89 x 89] intentionally omitted <==

• Annually in the US, 2.8 million people sustain a traumatic brain injury (TBI)

• 800,000 suffer a stroke

• 4.1 million TBIs globally in 2020[1]

==> picture [63 x 189] intentionally omitted <==

Neurology / physical rehabilitation are the only existing therapies

• One drug class for stroke (Suitable for less than 15% of patients)

• No treatment exists for TBI

==> picture [64 x 189] intentionally omitted <==

• High mortality

• Severe life-long disability

• High ongoing healthcare cost

==> picture [117 x 89] intentionally omitted <==

==> picture [117 x 89] intentionally omitted <==

==> picture [117 x 89] intentionally omitted <==

==> picture [452 x 16] intentionally omitted <==

----- Start of picture text -----

Minutes Hours Days
----- End of picture text -----

Initial injury size

Final injury size

1. Total TBIs in US, Germany, France, Italy, Spain, UK and Japan, Traumatic Brain Injury, Market Insight, Epidemiology and Market Forecast

, DelveInsight, published January 2021.

10

==> picture [89 x 89] intentionally omitted <==

==> picture [16 x 16] intentionally omitted <==

==> picture [16 x 16] intentionally omitted <==

==> picture [16 x 16] intentionally omitted <==

==> picture [16 x 16] intentionally omitted <==

==> picture [453 x 279] intentionally omitted <==

11

==> picture [89 x 89] intentionally omitted <==

==> picture [23 x 24] intentionally omitted <==

==> picture [454 x 260] intentionally omitted <==

----- Start of picture text -----

Primary Secondary Disability
Injury Injury Level
Hours Days Weeks Months
----- End of picture text -----

12

Walter Reed & UNSW Collaboration

==> picture [89 x 89] intentionally omitted <==

• Collaboration secured with the world-leading scientific teams at Walter Reed Army Institute of Research and UNSW Sydney

• Efficacy and mechanism of action studies to be conducted on Nyrada’s preclinical neuroprotection compound

==> picture [201 x 130] intentionally omitted <==

==> picture [126 x 126] intentionally omitted <==

• Aligns with Walter Reed’s mission to develop ground-breaking solutions to mitigate the impacts of traumatic brain injury which occurs in 1 in 25 military service members

Signals industry interest in Nyrada’s technology

==> picture [279 x 158] intentionally omitted <==

13

Program Status & Recent Achievements

==> picture [89 x 89] intentionally omitted <==

Proof-of-concept established

==> picture [30 x 41] intentionally omitted <==

==> picture [57 x 245] intentionally omitted <==

Lead optimisation well advanced

==> picture [34 x 40] intentionally omitted <==

==> picture [55 x 245] intentionally omitted <==

First-in-human studies (Phase I)

• Cholesterol-lowering Drug: late-CY 2021

• Brain Injury Drug: mid-CY 2022

==> picture [35 x 35] intentionally omitted <==

==> picture [15 x 16] intentionally omitted <==

Results from an in vivo cholesterol efficacy study showed a 57% reduction in total cholesterol (announced on 21 December 2020)

==> picture [15 x 15] intentionally omitted <==

Nyrada NYX-1010 showed excellent potency and blood-brain barrier penetration

14

==> picture [89 x 89] intentionally omitted <==

==> picture [91 x 124] intentionally omitted <==

==> picture [89 x 124] intentionally omitted <==

==> picture [91 x 124] intentionally omitted <==

==> picture [90 x 124] intentionally omitted <==

==> picture [90 x 124] intentionally omitted <==

==> picture [91 x 124] intentionally omitted <==

==> picture [762 x 93] intentionally omitted <==

15

==> picture [89 x 89] intentionally omitted <==

CY 2021 CY 2022

==> picture [13 x 13] intentionally omitted <==

==> picture [13 x 13] intentionally omitted <==

16

info@nyrada.com www.nyrada.com

==> picture [89 x 89] intentionally omitted <==

==> picture [219 x 219] intentionally omitted <==

Brain Injury Solution Animation

==> picture [214 x 214] intentionally omitted <==

Cholesterol-Lowering Animation

==> picture [49 x 48] intentionally omitted <==

==> picture [40 x 40] intentionally omitted <==

==> picture [40 x 40] intentionally omitted <==

@nyrada_inc

@nyrada_inc

ASX: NYR

17